Skip to main content

Intravesical Therapy of Interstitial Cystitis

  • Chapter
  • First Online:
Bladder Pain Syndrome – An Evolution
  • 625 Accesses

Abstract

Flashback to 1989. Bladder Pain Syndrome/Interstitial Cystitis was treated with a variety of off-label therapies, but the standard treatment against which all therapies were measured was intravesical lavage. Dimethyl sulfoxide (DMSO) had been approved a decade earlier (1978) for treatment of interstitial cystitis and remains to this day the only approved intravesical medication for the disorder by the Food and Drug Administration (FDA). Its use for this condition can be credited to Bruce Stewart of the Cleveland Clinic who persisted with an intravesical trial after failing in a transdermal clinical study of refractory patients in the mid-1960’s. It would be 1996 before sodium pentosan polysulfate became only the second approved medication and sole oral approved therapy for the syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lübbert M, Kyereme J, Schöbel N, Beltrán L, Wetzel CH, Hatt H. Transient receptor potential channels encode volatile chemicals sensed by rat trigeminal ganglion neurons. PLoS One. 2013;8(10):e77998.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Montgomery BD, Boorjian SA, Ziegelmann MJ, Joyce DD, Linder BJ. Intravesical silver nitrate for refractory hemorrhagic cystitis. Turk J Urol. 2016;42(3):197–201.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Jerkins GR, Noe HN, Hill DE. An unusual complication of silver nitrate treatment of hemorrhagic cystitis: case report. J Urol. 1986;136(2):456–8.

    Article  CAS  PubMed  Google Scholar 

  4. Kojima Y, Uchida K, Takiuchi H, Wakatsuki A, Sakurai T, Fujita Y, et al. Argyrosis of the urinary tract after silver nitrate instillation: report of a case. Hinyokika Kiyo. 1993;39(1):41–4.

    CAS  PubMed  Google Scholar 

  5. Kreder K, Lutgendorf S, Knopf MA, McGillis JP. Chlorpactin instillation releases calcitonin gene-related peptide in interstitial cystitis patients. Urology. 2001;57(6 Suppl 1):128–9.

    Article  CAS  PubMed  Google Scholar 

  6. Nickel JC, Downey J, Morales A, Emerson L, Clark J. Relative efficacy of various exogenous glycosaminoglycans in providing a bladder surface permeablility barrier. J Urol. 1998;160:612–4.

    Article  CAS  PubMed  Google Scholar 

  7. Hanno PM, Fritz R, Wein AJ. Heparin as an antibacterial agent in rabbit bladder. Urology. 1978;12:411–5.

    Article  CAS  PubMed  Google Scholar 

  8. Lane DA, Adams L. Non-anticoagulant uses of heparin. N Engl J Med. 1993;329:129–30.

    Article  CAS  PubMed  Google Scholar 

  9. Weaver RG, Dougherty TF, Natoli CA. Recent concepts of interstitial cystitis. J Urol. 1963;89:377–83.

    Article  CAS  PubMed  Google Scholar 

  10. Caulfield J, Phillips R, Steinhardt G. Intravesical heparin instillation: is there systemic absorption? J Urol. 1995;153:289A.

    Google Scholar 

  11. Lose G, Frandsen B, Hojensgard JC, Jespersen J, Astrup T. Chronic interstitial cystitis: increased levels of eosinophil cationic protein in serum and urine and an ameliorating effect of subcutaneous heparin. Scand J Urol Nephrol. 1983;17(2):159–61.

    Article  CAS  PubMed  Google Scholar 

  12. Lose G, Jespersen J, Frandsen B, Hojensgard JC, Astrup T. Subcutaneous heparin in the treatment of interstitial cystitis. Scand J Urol Nephrol. 1985;19(1):27–9.

    Article  CAS  PubMed  Google Scholar 

  13. Perez-Marrero R, Emerson LE, Maharajh DO, et al. Prolongation of response to DMSO by heparin maintenance. Urology. 1993;41(suppl):64–6.

    Article  CAS  PubMed  Google Scholar 

  14. Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994;73(5):504–7.

    Article  CAS  PubMed  Google Scholar 

  15. Kuo HC. Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and interstitial cystitis. J Formos Med Assoc. 2001;100(5):309–14.

    CAS  PubMed  Google Scholar 

  16. Parsons CL. Interstitial cystitis: new concepts in pathogenesis, diagnosis, and management. AUA News. 5(4):20–31.

    Google Scholar 

  17. Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology. 2005;65(1):45–8.

    Article  PubMed  Google Scholar 

  18. Welk BK, Teichman JM. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008;71(1):67–70.

    Article  PubMed  Google Scholar 

  19. Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MG. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103(7):910–8.

    Article  CAS  PubMed  Google Scholar 

  20. Nomiya A, Naruse T, Niimi A, Nishimatsu H, Kume H, Igawa Y, Homma Y. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. Int J Urol. 2013;20(11):1118–22.

    Article  CAS  PubMed  Google Scholar 

  21. Parsons CL, Koziol JA, Proctor JG, Zupkas P, Argade S. Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms. Can J Urol. 2015;22(2):7739–44.

    PubMed  Google Scholar 

  22. Gülpınar O, Kayış A, Süer E, Gökçe Mİ, Güçlü AG, Arıkan N. Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis. Can Urol Assoc J. 2014;8(9–10):E610–4.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Cervigni M. Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol. 2015;4(6):638–42.

    PubMed  PubMed Central  Google Scholar 

  24. Pyo JS, Cho WJ. Systematic review and meta-analysis of intravesical hyaluronic acid and hyaluronic acid/chondroitin sulfate instillation for interstitial cystitis/painful bladder syndrome. Cell Physiol Biochem. 2016;39(4):1618–25.

    Article  CAS  PubMed  Google Scholar 

  25. Lazzeri M, Hurle R, Casale P, Buffi N, Lughezzani G, Fiorini G, et al. Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence. Ther Adv Urol. 2016;8(2):91–9.

    Article  CAS  PubMed  Google Scholar 

  26. Cervigni M, Sommariva M, Tenaglia R. A randomized open label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethly sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2017;36(4):1178–86.

    Article  CAS  PubMed  Google Scholar 

  27. Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans--a review. Neurourol Urodyn. 2013;32(1):9–18.

    Article  CAS  PubMed  Google Scholar 

  28. Chintea CL, Belal M. Is there enough evidence for the use of intravesical instillations of glycosaminoglycan analogues in interstitial cystitis? BJU Int. 2013;111(2):192–3.

    Article  PubMed  Google Scholar 

  29. Zeidman EJ, Helfrick B, Pollard C, Thompson IM. Bacillus calmette-guerin immunotherapy for refractory interstitial cystitis. Urology. 1994;43(1):121–4.

    Article  CAS  PubMed  Google Scholar 

  30. Peters K, Diokno A, Steinert B, Yuhico M, Mitchell B, Krohta S, et al. The efficacy of intravesical tice strain bacillus calmette-guerin in the treatment of interstitial cystitis: a double-blind, prospective, placebo controlled trial. J Urol. 1997;157(6):2090–4.

    Article  CAS  PubMed  Google Scholar 

  31. Peters KM, Diokno AC, Steinert BW, Gonzalez JA. The efficacy of intravesical bacillus calmette-guerin in the treatment of interstitial cystitis: long-term followup. J Urol. 1998;159(5):1483–6.

    Article  CAS  PubMed  Google Scholar 

  32. Peters KM, Diokno AC, Steinert BW. Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille calmette-guerin treat interstitial cystitis by altering the immune profile in the bladder? Urology. 1999;54(3):450–3.

    Article  CAS  PubMed  Google Scholar 

  33. Peeker R, Haghsheno MA, Holmang S, Fall M. Intravesical bacillus calmette-guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol. 2000;164(6):1912–5.

    Article  CAS  PubMed  Google Scholar 

  34. Propert K, Mayer R, Nickel C, Peters K, Teal V, Burks D, et al. Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus calmette-guerin or placebo. J Urol. 2008;179(2):552–5.

    Article  PubMed  Google Scholar 

  35. Propert KJ, Mayer R, Nickel JC, Payne CK, Peters KM, Teal V, et al. Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus calmette-guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus calmette-guerin? J Urol. 2007;178(3 Pt 1):886–90.

    Article  PubMed  Google Scholar 

  36. Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, et al. A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol. 2005;173(4):1186–91.

    Article  PubMed  Google Scholar 

  37. Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol. 1999;162:3–11.

    Article  CAS  PubMed  Google Scholar 

  38. Lazzeri M, Beneforti P, Benaim G, Maggi CA, Lecci A, Turini D. Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. J Urol. 1996;156:947–52.

    Article  CAS  PubMed  Google Scholar 

  39. Lazzeri M, Beneforti P, Turini D, Barbagli G, Palminteri E. Single dose of intravesical resiniferatoxin for the treatment of interstitial cystitis -- preliminary results of a randomised controlled study. J Urol. 2000;163S:60.

    Google Scholar 

  40. Cruz F, Guimaraes M, Silva C, Rio ME, Coimbra A, Reis M. Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. J Urol. 1997;157:585–9.

    Article  CAS  PubMed  Google Scholar 

  41. Payne CK, Mosbaugh PG, Forrest JB, Evans RJ, Whitmore KE, Antoci JP, et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol. 2005;173(5):1590–4.

    Article  CAS  PubMed  Google Scholar 

  42. Ham BK, Kim JH, Oh MM, Lee JG, Bae JH. Effects of combination treatment of intravesical resiniferatoxin instillation and hydrodistention in patients with refractory painful bladder syndrome/interstitial cystitis: a pilot study. Int Neurourol J. 2012;16(1):41–6.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Peng CH, Kuo HC. Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis. Urol Int. 2007;78(1):78–81.

    Article  CAS  PubMed  Google Scholar 

  44. Lee WC, Chuang YC, Lee WC, Chiang PH. Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome. Kaohsiung J Med Sci. 2011;27(10):437–40.

    Article  CAS  PubMed  Google Scholar 

  45. Fraser MO, Chuang YC, Tyagi P, Yokoyama T, Yoshimura N, Huang L, et al. Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat. Urology. 2003;61(3):656–63.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Philip Hanno .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Hanno, P. (2018). Intravesical Therapy of Interstitial Cystitis. In: Hanno, P., Nordling, J., Staskin, D., Wein, A., Wyndaele, J. (eds) Bladder Pain Syndrome – An Evolution. Springer, Cham. https://doi.org/10.1007/978-3-319-61449-6_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-61449-6_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-61448-9

  • Online ISBN: 978-3-319-61449-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics